References
2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 25 Linguagem: Inglês
10.1161/circ.106.25.3373
ISSN1524-4539
Tópico(s)Folate and B Vitamins Research
ResumoHomeCirculationVol. 106, No. 25References Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBReferences Originally published17 Dec 2002https://doi.org/10.1161/circ.106.25.3373Circulation. 2002;106:3373–3421 References 1 National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. NIH Pub. No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993; 180 pages.Google Scholar2 National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation1994 ; 89:1333 -445.CrossrefMedlineGoogle Scholar3 Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: the Expert Panel. Arch Intern Med1988 ; 148:36 -69.CrossrefMedlineGoogle Scholar4 National Cholesterol Education Program. High Blood Cholesterol in Adults: Report of the Expert Panel on Detection, Evaluation, and Treatment. NIH Pub. No. 88-2925. Bethesda, MD: National Heart, Lung, and Blood Institute, 1988; 87 pages.Google Scholar5 National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. NIH Pub. No. 90-3046. Bethesda, MD: National Heart, Lung, and Blood Institute, 1990; 139 pages.Google Scholar6 Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation1991 ; 83:2154 -232.CrossrefMedlineGoogle Scholar7 Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA1998 ; 280:2099 -104.CrossrefMedlineGoogle Scholar8 Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science1986 ; 232:34 -47.CrossrefMedlineGoogle Scholar9 Glueck CJ, Gartside PF, Fallart RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med1976 ; 88:941 -57.MedlineGoogle Scholar10 Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation1998 ; 97:1837 -47.CrossrefMedlineGoogle Scholar11 Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA1986 ; 256:2823 -8.CrossrefMedlineGoogle Scholar12 Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease. JAMA1984 ; 251:351 -64.CrossrefMedlineGoogle Scholar13 Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA1984 ; 251:365 -74.CrossrefMedlineGoogle Scholar14 Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med1990 ; 323:1112 -9.CrossrefMedlineGoogle Scholar15 Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med1990 ; 322:1700 -7.CrossrefMedlineGoogle Scholar16 Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med1991 ; 115:687 -93.CrossrefMedlineGoogle Scholar17 Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet1999 ; 353:89 -92.CrossrefMedlineGoogle Scholar18 McGill HC Jr. Introduction to the geographic pathology of atherosclerosis. Lab Invest1968 ; 18:465 -7.MedlineGoogle Scholar19 Keys A, Arvanis C, Blackburn H. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980; 381 .Google Scholar20 Keys A, Menotti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohacek I, Nedeljkovic S, Puddu V, Punsar S, Taylor HL, Conti S, Kromhout D, Toshima H. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med1984 ; 13:141 -54.CrossrefMedlineGoogle Scholar21 Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis1974 ; 27:345 -64.CrossrefMedlineGoogle Scholar22 Toor M, Katchalsky A, Agmon J, Allalouf D. Atherosclerosis and related factors in immigrants to Israel. Circulation1960 ; 22:265 -79.CrossrefMedlineGoogle Scholar23 Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ1994; 308:367 -72.CrossrefMedlineGoogle Scholar24 Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl1999 ; (suppl S): S3-S8.Google Scholar25 Grundy SM, Wilhelmsen L, Rose G, Campbell RWF, Assmann G. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J1990 ; 11:462 -71.CrossrefMedlineGoogle Scholar26 People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China: baseline report from the P.R.C.-U.S.A. Collaborative Study. Circulation1992 ; 85:1083 -96.CrossrefMedlineGoogle Scholar27 Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ1994; 308:373 -9.CrossrefMedlineGoogle Scholar28 Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ1994; 308:363 -6.CrossrefMedlineGoogle Scholar29 McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, for the PDAY Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol1997 ; 17:95 -106.CrossrefMedlineGoogle Scholar30 McGill HC Jr, McMahan CA, and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young. Am J Cardiol1998 ; 82:30T -6T.CrossrefMedlineGoogle Scholar31 McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. Arterioscler Thromb Vasc Biol2000 ; 20:1998 -2004.CrossrefMedlineGoogle Scholar32 Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA1987 ; 257:2176 -80.CrossrefMedlineGoogle Scholar33 Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med1993 ; 328:313 -8.CrossrefMedlineGoogle Scholar34 Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA2000 ; 284:311 -8.CrossrefMedlineGoogle Scholar35 Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull WR Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of the intima of human arteries and of its atherosclerosisprone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation1992 ; 85:391 -405.CrossrefMedlineGoogle Scholar36 Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb1994 ; 14:840 -56.CrossrefMedlineGoogle Scholar37 Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation1995 ; 92:1355 -74.CrossrefMedlineGoogle Scholar38 Libby P. Molecular bases of the acute coronary syndromes. Circulation1995 ; 91:2844 -50.CrossrefMedlineGoogle Scholar39 Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med1998 ; 104(2A):14S -8S.CrossrefMedlineGoogle Scholar40 Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet1999 ; 353(suppl II): SII5-SII9.CrossrefMedlineGoogle Scholar41 Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation1998 ; 97:1195 -206.CrossrefMedlineGoogle Scholar42 Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol1995 ; 76:93C -7C.CrossrefMedlineGoogle Scholar43 Brown BG, Zhao XQ. Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, Inc., 2000:249 -72.Google Scholar44 Grundy SM. Cholesterol-lowering trials: a historical perspective. In: Grundy SM, ed. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:1 -329.Google Scholar References 45 Gordon DJ. Cholesterol lowering reduces mortality: the statins. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:299 -311.Google Scholar46 Holmes CL, Schulzer M, Mancini GB. Angiographic results of lipid-lowering trials: a systematic review and meta-analysis. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:191 -220.Google Scholar47 Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD, for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation2000 ; 102:1893 -900.CrossrefMedlineGoogle Scholar48 Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med1999 ; 341:410 -8.CrossrefMedlineGoogle Scholar49 Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol1998 ; 81:7B -12B.CrossrefMedlineGoogle Scholar50 Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J1998 ; 19(suppl M): M8-M14.MedlineGoogle Scholar51 Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med1980 ; 302:1383 -9.CrossrefMedlineGoogle Scholar52 Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol1998 ; 81:18B -25B.CrossrefMedlineGoogle Scholar53 Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation1990 ; 81:694 -6.CrossrefMedlineGoogle Scholar54 Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol1998 ; 81:13B -7B.MedlineGoogle Scholar55 Nordestgaard BG, Lewis B. Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain. Atherosclerosis1991 ; 87:39 -46.CrossrefMedlineGoogle Scholar56 Breslow JL. Mouse models of atherosclerosis. Science1996 ; 272:685 -8.CrossrefMedlineGoogle Scholar57 Weisgraber KH, Innerarity TL, Rall SC Jr, Mahley RW. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann NY Acad Sci1990 ; 598:37 -48.CrossrefMedlineGoogle Scholar58 Mahley RW, Weisgraber KH, Innerarity TL, Rall SC Jr. Genetic defects in lipoprotein metabolism: elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA1991 ; 265:78 -83.CrossrefMedlineGoogle Scholar59 Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation1981 ; 64:1174 -84.CrossrefMedlineGoogle Scholar60 Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation1987 ; 75:124 -30.CrossrefMedlineGoogle Scholar61 Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet1987 ; 2:62 -6.CrossrefMedlineGoogle Scholar62 Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation1993 ; 88:2762 -70.CrossrefMedlineGoogle Scholar63 Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation1993 ; 88[part 1]: 2180-9.CrossrefMedlineGoogle Scholar64 Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation1994 ; 90:42 -9.CrossrefMedlineGoogle Scholar65 Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD, Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis1996 ; 122:105 -15.CrossrefMedlineGoogle Scholar66 Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res2001 ; 42:17 -21.CrossrefMedlineGoogle Scholar67 Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis1999 ; 142:309 -15.CrossrefMedlineGoogle Scholar68 Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J1998 ; 19(suppl H): H31-H36.MedlineGoogle Scholar69 Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation2000 ; 102:1886 -92.CrossrefMedlineGoogle Scholar70 Kuchinskiene Z, Carlson LA. Composition, concentration, and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. J Lipid Res1982 ; 23:762 -9.CrossrefMedlineGoogle Scholar71 Miller KW, Small DM. Surface-to-core and interparticle equilibrium distributions of triglyceride-rich lipoprotein lipids. J Biol Chem1983 ; 258:13772 -84.CrossrefMedlineGoogle Scholar72 Bjorkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P, Ericsson C-G, Hamsten A. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation2000 ; 101:227 -30.LinkGoogle Scholar73 Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am1994 ; 78:117 -41.CrossrefMedlineGoogle Scholar74 Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am1990 ; 19:259 -78.CrossrefMedlineGoogle Scholar75 Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID Jr. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation1980 ; 61:302 -15.CrossrefMedlineGoogle Scholar76 Denke MA, Sempos CT, Grundy SM. Excess body weight: an underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med1993 ; 153:1093 -103.CrossrefMedlineGoogle Scholar77 Denke MA, Sempos CT, Grundy SM. Excess body weight: an under-recognized contributor to dyslipidemia in white American women. Arch Intern Med1994 ; 154:401 -10.CrossrefMedlineGoogle Scholar78 National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. NIH Pub. No. 98-4083. Bethesda, MD: National Heart, Lung and Blood Institute, 1998; 228 pages.Google Scholar79 National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obesity Res1998 ; 6(suppl 2): 51S-209S.CrossrefMedlineGoogle Scholar80 Hardman AE. Physical activity, obesity and blood lipids. Int J Obes Relat Metab Disord1999 ; 23(suppl 3): S64-S71.Google Scholar81 Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur J Med Res1997 ; 2:259 -64.MedlineGoogle Scholar82 Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest1973 ; 52:1544 -68.CrossrefMedlineGoogle Scholar83 Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol2000 ; 11:615 -20.CrossrefMedlineGoogle Scholar84 Wilson MA, Vega GL, Gylling H, Grundy SM. Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia. Arteriosclerosis Thrombosis1992 ; 12:976 -84.CrossrefMedlineGoogle Scholar85 Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. JAMA1985 ; 253:2398 -403.CrossrefMedlineGoogle Scholar86 Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med1990 ; 150:1313 -9.CrossrefMedlineGoogle Scholar87 Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med1994 ; 154:73 -82.CrossrefMedlineGoogle Scholar88 Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol1997 ; 79:1298 -301.CrossrefMedlineGoogle Scholar89 Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation1985 ; 71:881 -8.CrossrefMedlineGoogle Scholar90 Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation1989 ; 79:8 -15.CrossrefMedlineGoogle Scholar91 Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol1998 ; 81:26B -31B.CrossrefMedlineGoogle Scholar92 Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med2001 ; 161:1413 -9.CrossrefMedlineGoogle Scholar93 Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management[Editorial]? Arteriosclerosis1990 ; 10:668 -71.LinkGoogle Scholar References 94 Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis1993 ; 104:159 -71.CrossrefMedlineGoogle Scholar95 Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation1986 ; 73:978 -86.CrossrefMedlineGoogle Scholar96 Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol1988 ; 4(suppl A): 24A-30A.MedlineGoogle Scholar97 Marcovina S, Zoppo A, Graziani MS, Vassanelli C, Catapano AL. Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. La Ric Clin Lab1988 ; 18:319 -28.CrossrefMedlineGoogle Scholar98 Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med1990 ; 150:1629 -33.CrossrefMedlineGoogle Scholar99 Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis1991 ; 89:109 -16.CrossrefMedlineGoogle Scholar100 Levinson SS, Wagner SG. Measurement of apolipoprotein B-containing lipoproteins for routine clinical laboratory use in cardiovascular disease. Arch Pathol Lab Med1992 ; 116:1350 -4.MedlineGoogle Scholar101 Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol1992 ; 69:1015 -21.CrossrefMedlineGoogle Scholar102 Westerveld HT, Roeters van Lennep JE, Roeters van Lennep HW, Liem A-H, de Boo JA, van der Schouw YT, Erkelens W. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol1998 ; 18:1101 -7.CrossrefMedlineGoogle Scholar103 Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation2000 ; 101:477 -84.CrossrefMedlineGoogle Scholar104 Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard P-M, Dagenais GR, Despres J-P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation1996 ; 94:273 -8.CrossrefMedlineGoogle Scholar105 Lemieux I, Pascot A, Couillard C, Lamarche B, T chernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres J-P. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation2000 ; 102:179 -84.LinkGoogle Scholar106 Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation1979 ; 60:427 -39.CrossrefMedlineGoogle Scholar107 Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA1988 ; 260:3456 -60.CrossrefMedlineGoogle Scholar108 Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol1980 ; 46:649 -54.CrossrefMedlineGoogle Scholar109 Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis1996 ; 124(suppl 6): S11-S20.CrossrefMedlineGoogle Scholar110 Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature1991 ; 353:265 -7.CrossrefMedlineGoogle Scholar111 Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA1994 ; 91:9607 -11.CrossrefMedlineGoogle Scholar112 Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation1999 ; 100:1816 -22.CrossrefMedlineGoogle Scholar113 Tall AR. An overview of reverse cholesterol transport. Eur Heart J1998 ; 19(suppl A): A31-A35.MedlineGoogle Scholar114 van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest1995 ; 96:2758 -67.CrossrefMedlineGoogle Scholar115 Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res2000 ; 41:1495 -508.CrossrefMedlineGoogle Scholar116 Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res2000 ; 41:1481 -94.CrossrefMedlineGoogle Scholar117 Ng DS, Vezina C, Wolever TS, Kuksis A, Hegele RA, Connelly PW. Apolipoprotein A-I deficiency: biochemical and metabolic characteristics. Arterioscler Thromb Vasc Biol1995 ; 15:2157 -64.CrossrefMedlineGoogle Scholar118 Miller M, Aiello D, Pritchard H, Friel G, Zeller K. Apolipoprotein A-I Zavalla (Leu159→Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. Arterioscler Thromb Vasc Biol1998 ; 18:1242 -7.CrossrefMedlineGoogle Scholar119 Römling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC, Noseda G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb1994 ; 14:1915 -22.CrossrefMedlineGoogle Scholar120 Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa K. A new case of Apo A-I deficiency showing codon 8 nonsense mutation of the Apo A-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol1995 ; 15:1866 -74.CrossrefMedlineGoogle Scholar121 Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, von Eckardstein A, Assmann G. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I (L141R) Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation1996 ; 94:1622 -8.CrossrefMedlineGoogle Scholar122 Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol1996 ; 7:209 -16.CrossrefMedlineGoogle Scholar123 Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res1994 ; 35:871 -82.CrossrefMedlineGoogle Scholar124 Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides: assoc
Referência(s)